The End of Humira’s $200 Billion Drug Monopoly


The End of Humira’s $200 Billion Drug Monopoly

January 26, 2023

The End of Humira’s $200 Billion Drug Monopoly

After 20 years, Humira – the best selling drug of all time – is finally facing direct competition. Typically, once generic drugs arrive on a market they dominate sales and deliver big savings. But Humira’s competitors, known as biosimilars, aren’t like most other generics.

This week, what makes this prescription drug showdown so unusual – and so important.


Marta Wosińska, PhD, Visiting Fellow, Brookings Institution

Learn more and read a full transcript on our website.

Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.

Support this type of journalism today, with a gift.

Hosted on Acast. See for more information.

You may also like

Top Health Podcasts. Delivered to Your Inbox and Eardrums.

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Event and Media Partners

Buffer LinkedIn WhatsApp